If you have been reading about reverse-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-25. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility class | Soluble in water and DMSO | Dissolves readily |
| Typical storage temperature | -20 °C or lower | Long-term, desiccated |
| Standard purity method | Reverse-phase HPLC | Area normalization |
| Freeze-thaw guidance | Limit to three cycles | Aliquot in advance |
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
=== Lewis acid === SO3 is a strong Lewis acid readily forming adducts with Lewis bases. With pyridine, it gives the sulfur trioxide pyridine complex. Related adducts form from dioxane and trimethylamine.
=== RNA genomes === Like DNA, RNA can carry genetic information. RNA viruses have genomes composed of RNA that encodes a number of proteins. The viral genome is replicated by some of those proteins, while other proteins protect the genome as the virus particle moves to a new host cell. Viroids are another group of pathogens, but they consist only of RNA, do not encode any protein and are replicated by a host plant cell's polymerase.
A shift in substrate utilization can be induced by conditions such as eating or fasting, and the oxidation of either glucose or fatty acids tends to suppress the use of the other substrate (a phenomenon known as the Randle cycle). The intake of macronutrients stimulates the secretion and release of insulin and other chemical messengers such as glucagon-like peptide 1 (GLP-1), which act to regulate glucose levels, insulin sensitivity, satiety, and fat balance in the body. In the postprandial period, insulin is produced by the pancreas and serves to activate carbohydrate metabolism and stimulate glucose disposal in order to meet metabolic demands and prevent glucotoxicity. When insulin is unable to efficiently stimulate glucose utilization, the body's tissues become resistant to its hypoglycemic effects, promoting the development of a state of insulin resistance over time. This can happen because of chronic exposure to hyperinsulinemia due to poor diet, sedentary lifestyle, obesity, and other potentially modifiable risk factors. The phenomenon is similar to leptin resistance and can potentially lead to many deleterious health effects stemming from chronically elevated insulin levels, such as excessive fat storage and de novo synthesis, hepatic and peripheral insulin resistance, nonalcoholic fatty liver disease (NAFLD), hypertension and dyslipidemia, and decreased resting energy expenditure (REE) caused by impaired diet-induced thermogenesis.
One common issue faced by many cell lysis buffers is the disruption of protein structures during the lysis process, partially caused by use of detergents. Detergents often prevent the restoration of native conditions necessary for proper protein folding. For the longest time, after a detergent-based cell lysis, a buffer exchange and/or dialysis had to be performed to remove the detergent among other hindering compounds to restore native conditions. To overcome this a solution has emerged in the form of a detergent-free cell lysis buffer. The GentleLys buffer employs copolymers instead of detergents, ensuring efficient cell lysis while maintaining the native environment crucial for the correct folding of cellular components, such as proteins.
Sources: en.wikipedia.org
==== Minoxidil ==== Minoxidil, applied topically, is widely used for the treatment of hair loss. It may be effective in helping promote hair growth in both men and women with androgenic alopecia. About 40% of men experience hair regrowth after 3–6 months. It is the only topical product that is FDA approved in America for androgenic hair loss. However, increased hair loss has been reported.
=== Nerve supply === Innervation derives from spinal cord segments S2 to S4, reaching the penis through the pelvic splanchnic nerves and the pudendal nerves. The dorsal nerve of the penis, a branch of the pudendal nerve, runs alongside the dorsal artery and supplies the skin and the glans. It travels deep to Buck's fascia within the dorsal neurovascular bundle, in the groove between the corpora cavernosa. The cavernous nerves carry the parasympathetic fibres that innervate the helicine arteries supplying the erectile tissue.
== Further reading == Hill, A. V.; Long, C. N. H.; Lupton, H. (1924). "Muscular Exercise, Lactic Acid, and the Supply and Utilisation of Oxygen". Proceedings of the Royal Society B: Biological Sciences. 96 (679): 438–75. doi:10.1098/rspb.1924.0037. JSTOR 81203. Laforgia, J.; Withers, R. T.; Gore, C. J. (2006). "Effects of exercise intensity and duration on the excess post-exercise oxygen consumption". Journal of Sports Sciences. 24 (12): 1247–64. doi:10.1080/02640410600552064. PMID 17101527. S2CID 25579756. Lee, C. G. (2003). "Excess post-exercise oxygen consumption in adult sockeye (Oncorhynchus nerka) and coho (O. Kisutch) salmon following critical speed swimming". Journal of Experimental Biology. 206 (18): 3253–60. doi:10.1242/jeb.00548. PMID 12909706. Thornton, M. K.; Potteiger, J. A. (2002). "Effects of resistance exercise bouts of different intensities but equal work on EPOC". Medicine & Science in Sports & Exercise. 34 (4): 715–22. doi:10.1249/00005768-200204000-00024. PMID 11932584. Gore, C. J.; Withers, R. T. (1990). "The effect of exercise intensity and duration on the oxygen deficit and excess post-exercise oxygen consumption". European Journal of Applied Physiology and Occupational Physiology. 60 (3): 169–74. doi:10.1007/BF00839153. PMID 2347316. S2CID 11724610. Lee, C. G.; Devlin, R. H.; Farrell, A. P. (2003). "Swimming performance, oxygen consumption and excess post-exercise oxygen consumption in adult transgenic and ocean-ranched coho salmon". Journal of Fish Biology. 62 (4): 753–66. doi:10.1046/j.1095-8649.2003.00057.x.
Sources: en.wikipedia.org
Crush syndrome (also traumatic rhabdomyolysis, Bywaters' syndrome, or smiling death) is a medical condition characterized by major shock and kidney failure after a crushing injury to skeletal muscle. It should not be confused with crush injury, which is the compression of the arms, legs, or other parts of the body that causes muscle swelling and/or neurological disturbances in the affected areas of the body, while crush syndrome is a localized crush injury with systemic manifestations. Cases occur commonly in catastrophes such as earthquakes, to individuals who have been trapped under fallen or moving masonry. People with crushing damage present some of the greatest challenges in field medicine, and may need a physician's attention on the site of their injury. Appropriate physiological preparation of the injured is mandatory. It may be possible to free the patient without amputation; however, field amputations may be necessary in drastic situations.
=== Pharmacokinetics === DOPR crosses the blood–brain barrier in rodents. The drug showed the highest brain/plasma ratio among DOM homologues in rodents, whereas 2,5-dimethoxyamphetamine (2,5-DMA) showed the lowest. This was involved in potency differences between the drugs.
Burton, Bonnie (October 15, 2014). "'Pink slime' in burgers? McDonald's hires former MythBuster to find out". CNET. Retrieved March 25, 2016. Runge, Kristin (March 23, 2016). "Pink Slimed: The Beef Industry Learns The Importance Of Social Media Literacy". Wisconsin Public Radio. Retrieved March 24, 2016.
Sources: en.wikipedia.org
Cold storage at minus twenty degrees Celsius or below is typical, with desiccant and protection from light. The solid form is far more stable than any solution.
Repeated freeze-thaw cycles, alkaline pH, and exposure to light or oxygen are the main drivers. Moisture uptake by the solid also matters.
Mass spectrometry provides the strongest single identity check by matching the observed molecular ion to the expected value. Chromatographic retention time alone is not sufficient.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.